EchoSolv AS vs AI-CVD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Echo IQ
VS
by HeartLung AI

AI Verdict

EchoSolv AS is designed for specific clinical decision support, identifying patients at risk for severe aortic stenosis using echocardiogram measurements. In contrast, AI-CVD focuses on opportunistic screening for a broader range of cardiovascular and multisystem diseases by analyzing existing CT scans for quantitative measurements like coronary artery calcium and cardiac chamber volumetry. Therefore, while both are cardiology AI tools, they serve different diagnostic purposes and utilize different imaging modalities.

Choose EchoSolv AS if…

Choose EchoSolv AS if your cardiology department requires an AI-powered clinical decision support platform specifically designed to accurately and efficiently identify patients at high risk for severe aortic stenosis from echocardiogram measurements. This tool is ideal for integrating into existing PACS workflows to provide ultra-fast risk detection and second reader support, helping prioritize studies for closer review.

View EchoSolv AS →

Choose AI-CVD if…

Choose AI-CVD if your institution seeks to implement opportunistic screening for a broad spectrum of cardiovascular and multisystem diseases by leveraging existing chest and abdominal CT scans. This platform is best suited for automatically deriving anatomical and density-based measurements, such as coronary artery calcium scoring and cardiac chamber volumetry, to enable early detection of hidden health risks without additional imaging or workflow disruption.

View AI-CVD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature EchoSolv AS AI-CVD
Deployment Cloud-based Unknown
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Unknown
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS emphasizes ultra-fast risk detection (under 3 seconds) and seamless integration into existing workflows, requiring no EMR integration and integrating directly with PACS. This focus on speed and minimal disruption makes it highly usable for its specific application.

Clinical Value

AI-CVD

AI-CVD offers broader clinical value by performing opportunistic screening for a wide range of cardiovascular and multisystem diseases (including CAC scoring, cardiac chamber volumetry, and bone mineral density) from existing CT scans. This approach maximizes the utility of already acquired data for early detection and preventive care across a larger patient population.

Pricing & Value

EchoSolv AS

EchoSolv AS provides a clear pathway for value realization by identifying a miscellaneous reimbursement code (93799) with an expected rate of US$100 to US$150 per use. This transparency in potential reimbursement offers a tangible value proposition for healthcare providers.

Enterprise Readiness

EchoSolv AS

EchoSolv AS explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), alongside FDA clearance and cloud-based deployment with PACS integration. These definitive statements indicate a higher level of enterprise readiness compared to Tool B's 'likely' status for BAA and HIPAA.

Innovation

AI-CVD

AI-CVD demonstrates greater innovation by transforming routine CT scans, already performed for other reasons, into a comprehensive, multi-disease opportunistic screening platform. This approach leverages existing data to proactively identify a wide array of hidden health risks across cardiovascular and multisystem domains.

Support & Docs

EchoSolv AS

EchoSolv AS explicitly mentions an 'extensive suite of supporting documentation' to assist hospitals with reimbursement processes and a 'Clinician user manual'. This indicates a strong commitment to providing comprehensive resources for both clinical use and administrative support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature EchoSolv AS AI-CVD
Name EchoSolv AS AI-CVD
Company Echo IQ HeartLung Corporation
Description EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows. AI-CVDu00ae is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.
Primary Input Echocardiograms Existing CT scans (chest and abdominal)
Key Focus Identify high-probability severe aortic stenosis (sAS) patients Opportunistic screening for cardiovascular and multisystem diseases
Specialties Cardiology, Cardiothoracic Surgery Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring EchoSolv AS and AI-CVD.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

EchoSolv AS analyzes numerical measurements derived from echocardiograms to identify patients at risk for severe aortic stenosis. In contrast, AI-CVD performs opportunistic screening for various diseases by utilizing existing chest and abdominal CT scans.
EchoSolv AS is specifically designed to identify patients with a high probability of severe aortic stenosis. AI-CVD offers broader opportunistic screening for cardiovascular and multisystem diseases, including coronary artery calcium scoring, aortic and mitral valve calcium analysis, and cardiac chamber volumetry.
EchoSolv AS is designed to fit existing workflows, integrating with PACS and not requiring EMR integration. AI-CVD leverages existing CT scans, meaning it requires no additional imaging, radiation, contrast, or disruption to current workflows.
EchoSolv AS provides AI-powered clinical decision support for severe AS probability, consistent guideline checks from measurements, and second reader support. AI-CVD delivers automated CT-derived anatomical and density-based measurements, such as epicardial fat volumetry and aorta/pulmonary artery sizing.
EchoSolv AS is primarily relevant for Cardiology and Cardiothoracic Surgery due to its focus on aortic stenosis. AI-CVD has a broader application, relevant for Cardiology, Pulmonology, and Radiology, given its multisystem screening capabilities from CT scans.
AI Tool Finder
AI-powered search. Results may not be comprehensive.